Keen Players Bank on Novel Treatment Offerings for Growth in Global Glioblastoma Multiforme Treatment Market

Keen players in the global glioblastoma multiforme (GBM) treatment market are striving to maintain their foothold via novel product offerings. These players are focusing hard on the development of newer biological drugs with fewer side effects, which are usually associated with the consumption of immunosuppressants and chemotherapeutic agents.

Collaborations with diagnostic laboratories in order to raise awareness regarding treatment options for glioblastoma multiforme is another key growth strategy adopted by market players to build a strong market presence.

A report by Transparency Market Research projects the global glioblastoma multiforme treatment market will rise at a solid 11.40% CAGR between 2014 and 2022. At this pace, the market is expected to become worth US$0.91 bn by the end of 2022 increasing from US$0.34 bn in 2013.

In this blog post, analysts present answers to some of the pertinent questions regarding developments in the global GBM treatment market:

Q. What are the key factors stoking growth of the global GBM treatment market?

A. The high prevalence of glioblastoma multiforme, which is one of the lethal primary brain tumors among adults is the key factor stoking growth of glioblastoma multiforme treatment market. The inefficacy of the present line of treatment for glioblastoma multiforme to increase the survival rate of patients is necessitating the development of newer treatment modalities. The available treatments are also ineffective to prevent the frequent recurrence of the condition, invasive in nature, and resistance of glioma stem cells for them is leading to an increased demand for novel treatment modalities. 

Rising geriatric population globally prone to GBM and involvement of various government and non-government organizations that are raising awareness against GBM is further providing a boost to the global GBM treatment market. 

The high resistance of GBM to DNA modifying agents resulting in limitations of available therapies is displaying a desperate need for novel therapeutics. GBM pipeline comprising a mix of small molecules, biological, immunotherapy, and other types of therapeutics is stimulating the development of a novel line of treatment.

Recent advances in molecular biology and gene technology have extended novel treatment possibilities for the treatment of glioblastoma multiforme.

Q. Which are the leading regional markets for glioblastoma multiforme treatment?

A. North America, amongst all, occupies the leading position in the global glioblastoma multiforme treatment market mainly due to the high prevalence of glioblastoma multiforme in the region. In the region, National Brain Tumor Society, the Brain Tumor Foundation of Canada, and the American Brain Tumor Association are some of the bodies that are actively involved in raising awareness regarding GBM. This is aiding the growth of North America market for glioblastoma multiforme treatment.

Q. Which is the key drug in the global GBM treatment market?

A. Among the several treatment modalities for glioblastoma multiforme, temozolomide dominated the global GBM treatment market in 2013. However, the recent loss of patent of the drug has led generic drugs to foray into the market. This has significantly impacted the market share of temozolomide.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports